Sling vs Botox for Mixed Incontinence

Treatment for Mixed Urinary Incontinence: Mid-urethral Sling vs. Botox A

Patrocinadores

Patrocinador principal: NICHD Pelvic Floor Disorders Network

Colaborador: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Women and Infants Hospital of Rhode Island
Duke University
University of Pennsylvania
University of Pittsburgh
University of California, San Diego
Kaiser Permanente
University of Texas Southwestern Medical Center
University of Alabama at Birmingham
RTI International

Fuente NICHD Pelvic Floor Disorders Network
Resumen breve

The primary aim is to compare the effectiveness of intradetrusor injection of 100 unit injection of Botulinum toxin A to mid-urethral sling for change in MUI symptoms 6 months following treatment.

Descripción detallada

Mixed urinary incontinence (MUI), defined as the presence of both stress urinary incontinence (SUI) and urgency urinary incontinence (UUI), is a challenging condition for which clinicians frequently use multiple sequential treatments that have undergone limited evaluation in rigorous clinical trials. The Mixed Urinary Incontinence: Mid-urethral Sling vs. Botox A (MUSA) trial will estimate the effect of Botulinum toxin A (Botox A ®) compared to mid-urethral sling for the treatment of MUI symptoms in 146 women. MUSA is a randomized 2-arm clinical trial.

The purpose of MUSA is to:

- compare treatment with either Botulinum toxin A (Botox A ®) or mid-urethral sling for women with MUI

- characterize patient characteristics associated with treatment response

The primary objective is to estimate the effect of intradetrusor injections Botulinum toxin A (Botox A ®) compared to mid-urethral sling for treatment of MUI in 146 women 6 months after treatment. The change in severity of MUI symptoms will be measured using the Urogenital Distress Inventory.

Secondary objectives include identifying predictors of treatment failure and cost-effectiveness of treatments in this MUI population.

Estado general Recruiting
Fecha de inicio July 8, 2020
Fecha de Terminación June 2021
Fecha de finalización primaria June 2021
Fase Phase 3
Tipo de estudio Interventional
Resultado primario
Medida Periodo de tiempo
Change in Urogenital Distress Inventory (UDI) Total Score Baseline until 6 months
Resultado secundario
Medida Periodo de tiempo
Change in Urogenital Distress Inventory (UDI) Stress Subscore Baseline until 6 months
Change in Urogenital Distress Inventory (UDI) Irritative Sub-Score Baseline until 6 months
Change in Urogenital Distress Inventory (UDI) Total Score Baseline until 3 months
Inscripción 146
Condición
Intervención

Tipo de intervención: Drug

Nombre de intervención: Botox® injection

Descripción: Botulinum toxin A will be prepared by dissolving 100 units of botulinum toxin A into 10 ml of injectable saline. Indigo carmine or methylene blue 0.1 ml will be added to each syringe of botulinum toxin A. The treating physician will inject a total of 10 ml of the Botox A® into approximately 15 to 20 different detrusor muscle sites under direct visualization.

Etiqueta de grupo de brazo: Botox A® injection

Tipo de intervención: Device

Nombre de intervención: Mid-urethral sling

Descripción: Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. "Mini-sling" and "single-incision" sling will not be allowed due to potential risk for higher failure rate.

Etiqueta de grupo de brazo: Mid-urethral sling

Elegibilidad

Criterios:

Inclusion Criteria:

1. Reporting at least "moderate bother" from UUI item on UDI

* "Do you experience urine leakage associated with a feeling of urgency?"

2. Reporting at least "moderate bother" from SUI item on UDI

* "Do you experience urine leakage related to physical activity, coughing, or sneezing?"

3. Diagnosis of SUI defined by a positive cough stress test (CST) or UDE within the past 18 months

4. Presence of UUI on bladder diary with > 4 Urgency IE/3-day diary

5. Urinary symptoms >3 months

6. Persistent symptoms despite at least one or more conservative treatments (e.g. supervised behavioral therapy, physical therapy) as determined adequate by the physician.

7. Inadequate response to oral overactive bladder medications (including anti-cholinergic and/or beta-mimetic medication) unless patient is

1. intolerant of oral overactive bladder medications, or

2. oral overactive bladder medications are contraindicated as determined by the treating provider.

8. Urodynamics within past 18 months

9. Demonstrates ability (or have caregiver demonstrate ability) to perform clean intermittent self-catheterization.

Exclusion Criteria:

1. Anterior or apical compartment prolapse at or beyond the hymen (>0 on POPQ), regardless if patient is symptomatic

* Women with anterior or apical prolapse above the hymen (<0) who do not report vaginal bulge symptoms will be eligible

2. Planned concomitant surgery for anterior vaginal wall or apical prolapse > 0

* Women undergoing only rectocele repair or other repair unrelated to anterior or apical compartment are eligible

3. Women undergoing hysterectomy for any indication will be excluded

4. Active pelvic organ malignancy

5. Age <21 years

6. Pregnant or plans for future pregnancy in next 6 months, or within 12 months post-partum

7. Post-void residual >150 cc on 2 occasions within the past 6 months, or current catheter use

8. Participation in other trial that may influence results of this study

9. Unevaluated hematuria

10. Prior sling, synthetic mesh for prolapse, implanted nerve stimulator for urinary incontinence

11. Spinal cord injury or advanced/severe neurologic conditions including Multiple Sclerosis, Parkinsons, Myasthenia Gravis, Charcot-Marie-Tooth

12. Women on overactive bladder medication/therapy will be eligible after 3 week wash-out period

13. Non-ambulatory

14. History of serious adverse reaction to synthetic mesh

15. Not able to complete study assessments per clinician judgment, or not available for 6 month follow-up

16. Diagnosis of and/or history of bladder pain or chronic pelvic pain

17. Women who had intravesical Botox injection within the past 12 months

18. Women who have undergone anterior or apical pelvic organ prolapse repair within the past 6 months

Género: Female

Basado en el género: Yes

Edad mínima: 21 Years

Edad máxima: N/A

Voluntarios Saludables: No

Oficial general
Ubicación
Instalaciones: Estado: Contacto: Investigador:
University of Alabama at Birmingham, Department of Obstetrics and Gynecology | Birmingham, Alabama, 35249, United States Recruiting Holly Richter, PhD, MD 205-934-1704 [email protected] Holly E Richter, PhD, MD Principal Investigator
University of California at San Diego | La Jolla, California, 92037-0974, United States Recruiting Emily Lukacz, MD 858-657-8435 [email protected] Emily Lukacz, MD Principal Investigator
Kaiser Permanente | San Diego, California, 92110, United States Not yet recruiting Shawn Menefee, MD 619-221-6200 [email protected] Shawn Menefee Principal Investigator
Duke University, Duke Division of Urogynecology and Reconstructive Pelvic Surgery | Durham, North Carolina, 27707, United States Not yet recruiting Anthony G Visco, MD 919-401-1006 [email protected] Anthony G Visco, MD Principal Investigator
University of Pennsylvania | Philadelphia, Pennsylvania, 19104, United States Recruiting Heidi Harvie, MD 215-662-4147 [email protected] Heidi Harvie, MD Principal Investigator
Magee-Women's Hospital, Department of Obstetrics and Gynecology | Pittsburgh, Pennsylvania, 15213, United States Recruiting Halina M Zyczynski, MD 412-641-1440 [email protected] Halina M Zyczynski, MD Principal Investigator
Brown/ Women and Infants Hospital of Rhode Island, Center for Women's Pelvic Medicine and Reconstructive Surgery | Providence, Rhode Island, 02903, United States Recruiting Vivian Sung, MD 401-453-7560 [email protected] Vivian Sung, MD Principal Investigator
University of Texas Southwestern Medical Center | Dallas, Texas, 75390, United States Not yet recruiting David Rahn, MD 214-648-6430 [email protected]
Ubicacion Paises

United States

Fecha de verificación

July 2020

Fiesta responsable

Tipo: Sponsor

Palabras clave
Tiene acceso ampliado No
Condición Examinar
Número de brazos 2
Grupo de brazo

Etiqueta: Botox A® injection

Tipo: Active Comparator

Descripción: A dose of 100 units of Botulinum toxin A will be injected into the bladder. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.

Etiqueta: Mid-urethral sling

Tipo: Active Comparator

Descripción: Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.

Acrónimo MUSA
Datos del paciente No
Información de diseño del estudio

Asignación: Randomized

Modelo de intervención: Parallel Assignment

Descripción del modelo de intervención: At 6 months, the effect of treatment with Botox A or mid-urethral sling will be evaluated within a classic RCT model. The analysis will determine the effect of treatment on the primary outcome, change in Urogenital Distress Inventory (UDI) score at 6 months.

Propósito primario: Treatment

Enmascaramiento: None (Open Label)

Fuente: ClinicalTrials.gov